Reports
Sale
Neovascular Age-Related Macular Degeneration Treatment Market: By Drug Type: Ranibizumab, Aflibercept, Bevacizumab, Brolucizumab, Faricimab, Others; By Disease Type: Dry AMD, Wet AMD; By Age Group: Less Than 60, Others; By Disease Stage; By Gender; By Distribution Channel; Regional Analysis; Supplier Landscape; 2024-2032
Neovascular Age-Related Macular Degeneration Treatment Market Outlook
The neovascular age-related macular degeneration treatment market size was valued at USD 11 billion in 2023 in the 7 major markets, driven by the increasing advancements in treatment technologies for neovascular AMD across the globe. The market size is anticipated to grow at a CAGR of 7.5% during the forecast period of 2024-2032 to achieve a value of USD 21.1 billion by 2032.
Neovascular Age-Related Macular Degeneration Treatment: Introduction
Neovascular age-related macular degeneration (AMD) treatment are the several therapeutic interventions and strategies that target the progression management this specific form of AMD. Neovascular AMD, also known as wet AMD, is recognized as the growth of abnormal blood vessels beneath the macula, which can lead to severe vision loss if left untreated. The primary purpose of treatment is to slow down or prevent further vision loss and preserve visual function in the patient. The use of anti-vascular endothelial growth factor (anti-VEGF) medications is the most common and effective treatment approach for neovascular AMD. These medications are administered through injections into the eye. These medicines block the growth of abnormal blood vessels and reduce leakage and inflammation in the retina. Examples of anti-VEGF drugs used in neovascular AMD treatment include ranibizumab, aflibercept, and bevacizumab.
Neovascular Age-Related Macular Degeneration Treatment Market Analysis
The increasing prevalence of neovascular AMD globally is mainly due to the geriatric population. With rise in geriatric population, increase in demand for effective treatments for neovascular AMD is expected to increase as well. The market is encountering continuous technological advancements in treatment modalities for neovascular AMD and these advancements are expected to continue in coming years as well contributing to the neovascular age-related macular degeneration treatment market growth. The market expansion is being further fueled by the continuing research and development projects being made to increase treatment efficacy, decrease treatment frequency, and investigate alternative therapies.
With increasing awareness of the genetic and molecular factors contributing to neovascular AMD, there is a substantial shift towards personalized medicine across the 7 major markets. Targeted therapies and genetic testing are being explored to identify subgroups of patients who may respond better to specific treatments, allowing for more tailored and effective management accelerating the market growth.
Additionally, the integration of digital technologies, such as telemedicine and remote monitoring into neovascular AMD management is being increasing, further contributing to the market growth. Remote monitoring of disease progression and treatment response allows for more efficient patient management, reduces the need for frequent hospital visits, and enhances patient care.
Neovascular Age-Related Macular Degeneration Treatment Market Segmentations
Market Breakup by Drug Type
- Ranibizumab
- Aflibercept
- Bevacizumab
- Brolucizumab
- Faricimab
- Others
Market Breakup by Disease Type
- Dry AMD
- Wet AMD
Market Breakup by Age Group
- Less Than 60
- Between 60 to 80
- More Than 80
Market by Disease Stage
- Early-Stage AMD
- Intermediate Stage AMD
- Late-Stage AMD
Market by Gender
- Male
- Female
Market by Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Market Breakup by Region- 7MM
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
Neovascular Age-Related Macular Degeneration Treatment Market Overview
The global population is aging, and advanced age is a significant risk factor for neovascular AMD. As the geriatric population continues to grow, the demand for neovascular AMD treatments is expected to increase, furth driving the neovascular age-related macular degeneration treatment market growth. The prevalence of neovascular AMD is also on the rise due to factors such as increasing life expectancy and lifestyle changes among people globally. The rising number of neovascular AMD patients is creating a substantial market demand for effective treatments contributing to the market growth. There have been multiple campaigns to increase awareness against AMD, patient education initiatives, and neovascular AMD screening programs which are substantially improving early detection rates as people. For quick action and the best possible treatment options, neovascular AMD must be identified early and accurately diagnosed. Furthermore, improvements in imaging methods like optical coherence tomography (OCT) and fluorescein angiography are enabling better neovascular AMD diagnosis and monitoring, which is further fuelling the market's need for related treatment choices internationally.
Neovascular Age-Related Macular Degeneration Treatment Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- F. Hoffmann-La Roche Ltd
- Bausch & Lomb
- Novartis AG
- Pfizer, Inc.
- AbbVie Inc.
- Santen Pharmaceutical Co., Ltd.
- Ophthotech Corporation
- Alimera Sciences
- GSK plc.
- Bayer AG
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Drug Type |
|
| Breakup by Disease Type |
|
| Breakup by Age Group |
|
| Breakup by Disease Stage |
|
| Breakup by Gender |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Neovascular Age-Related Macular Degeneration Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Neovascular Age-Related Macular Degeneration Epidemiology Analysis – 7MM
5.1 7MM Epidemiology Scenario Overview (2017-2032)
5.2 United States Neovascular Age-Related Macular Degeneration Treatment Epidemiology (2017-2032)
5.3 EU-4 and United Kingdom Neovascular Age-Related Macular Degeneration Treatment Epidemiology (2017-2032)
5.3.1 Germany Neovascular Age-Related Macular Degeneration Epidemiology Forecast (2017-2032)
5.3.2 France Neovascular Age-Related Macular Degeneration Epidemiology Forecast (2017-2032)
5.3.3 Italy Neovascular Age-Related Macular Degeneration Epidemiology Forecast (2017-2032)
5.3.4 Spain Neovascular Age-Related Macular Degeneration Epidemiology Forecast (2017-2032)
5.3.5 United Kingdom Neovascular Age-Related Macular Degeneration Epidemiology Forecast (2017-2032)
5.4 Japan Neovascular Age-Related Macular Degeneration Treatment Epidemiology (2017-2032)
6 Neovascular Age-Related Macular Degeneration Treatment Market Overview – 7MM
6.1 Neovascular Age-Related Macular Degeneration Treatment Market Historical Value (2017-2023)
6.2 Neovascular Age-Related Macular Degeneration Treatment Market Forecast Value (2024-2032)
7 Neovascular Age-Related Macular Degeneration Treatment Market Landscape – 7MM
7.1 Neovascular Age-Related Macular Degeneration Treatment: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Neovascular Age-Related Macular Degeneration Treatment: Product Landscape
7.2.1 Analysis by Drug Type
7.2.2 Analysis by Application
7.2.3
8 Neovascular Age-Related Macular Degeneration Treatment Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Neovascular Age-Related Macular Degeneration Treatment Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Neovascular Age-Related Macular Degeneration Treatment Market Segmentation – 7MM
11.1 Neovascular Age-Related Macular Degeneration Treatment Market by Drug Type
11.1.1 Market Overview
11.1.2 Ranibizumab
11.1.3 Aflibercept
11.1.4 Bevacizumab
11.1.5 Brolucizumab
11.1.6 Faricimab
11.1.7 Others
11.2 Neovascular Age-Related Macular Degeneration Treatment Market by Disease Type
11.2.1 Market Overview
11.2.2 Dry AMD
11.2.3 Wet AMD
11.3 Neovascular Age-Related Macular Degeneration Treatment Market by Age Group
11.3.1 Market Overview
11.3.2 Less Than 60
11.3.3 Between 60 to 80
11.3.4 More Than 80
11.4 Neovascular Age-Related Macular Degeneration Treatment Market by Disease Stage
11.4.1 Market Overview
11.4.2 Early-Stage AMD
11.4.3 Intermediate Stage AMD
11.4.4 Late-Stage AMD
11.5 Neovascular Age-Related Macular Degeneration Treatment Market by Gender
11.5.1 Market Overview
11.5.2 Male
11.5.3 Female
11.6 Neovascular Age-Related Macular Degeneration Treatment Market by Distribution Channel
11.6.1 Market Overview
11.6.2 Hospital Pharmacy
11.6.3 Retail Pharmacy
11.6.4 Online Pharmacy
11.7 Neovascular Age-Related Macular Degeneration Treatment Market by Region
11.7.1 Market Overview
11.7.2 United States
11.7.3 EU-4 and the United Kingdom
11.7.3.1 Germany
11.7.3.2 France
11.7.3.3 Italy
11.7.3.4 Spain
11.7.3.5 United Kingdom
11.7.4 Japan
12 United States Neovascular Age-Related Macular Degeneration Treatment Market
12.1 Neovascular Age-Related Macular Degeneration Treatment Market Historical Size (2017-2023)
12.2 Neovascular Age-Related Macular Degeneration Treatment Market Forecast Size (2024-2032)
12.3 Neovascular Age-Related Macular Degeneration Treatment Market by Drug Type
12.4 Neovascular Age-Related Macular Degeneration Treatment Market by Disease Type
13 EU-4 and United Kingdom Neovascular Age-Related Macular Degeneration Treatment Market
13.1 Neovascular Age-Related Macular Degeneration Treatment Market Historical Value (2017-2023)
13.2 Neovascular Age-Related Macular Degeneration Treatment Market Forecast Value (2024-2032)
13.3 Germany Neovascular Age-Related Macular Degeneration Treatment Market Overview
13.3.1 Neovascular Age-Related Macular Degeneration Treatment Market by Drug Type
13.3.2 Neovascular Age-Related Macular Degeneration Treatment Market by Disease Type
13.4 France Neovascular Age-Related Macular Degeneration Treatment Market Overview
13.4.1 Neovascular Age-Related Macular Degeneration Treatment Market by Drug Type
13.4.2 Neovascular Age-Related Macular Degeneration Treatment Market by Disease Type
13.5 Italy Neovascular Age-Related Macular Degeneration Treatment Market Overview
13.5.1 Neovascular Age-Related Macular Degeneration Treatment Market by Drug Type
13.5.2 Neovascular Age-Related Macular Degeneration Treatment Market by Disease Type
13.6 Spain Neovascular Age-Related Macular Degeneration Treatment Market Overview
13.6.1 Neovascular Age-Related Macular Degeneration Treatment Market by Drug Type
13.6.2 Neovascular Age-Related Macular Degeneration Treatment Market by Disease Type
13.7 United Kingdom Neovascular Age-Related Macular Degeneration Treatment Market Overview
13.7.1 Neovascular Age-Related Macular Degeneration Treatment Market by Drug Type
13.7.2 Neovascular Age-Related Macular Degeneration Treatment Market by Disease Type
14 Japan Neovascular Age-Related Macular Degeneration Treatment Market
14.1 Neovascular Age-Related Macular Degeneration Treatment Market Historical Value (2017-2023)
14.2 Neovascular Age-Related Macular Degeneration Treatment Market Forecast Value (2024-2032)
14.3 Neovascular Age-Related Macular Degeneration Treatment Market by Disease Type
14.4 Neovascular Age-Related Macular Degeneration Treatment Market by Treatment Type
15 Regulatory Framework
15.1 Regulatory Overview
15.1.1 US FDA
15.1.2 EU EMA
15.1.3 JAPAN PMDA
16 Patent Analysis
16.1 Analysis by Type of Patent
16.2 Analysis by Publication year
16.3 Analysis by Issuing Authority
16.4 Analysis by Patent Age
16.5 Analysis by CPC Analysis
16.6 Analysis by Patent Valuation
16.7 Analysis by Key Players
17 Grants Analysis
17.1 Analysis by Year
17.2 Analysis by Amount Awarded
17.3 Analysis by Issuing Authority
17.4 Analysis by Grant Application
17.5 Analysis by Funding Institute
17.6 Analysis by NIH Departments
17.7 Analysis by Recipient Organization
18 Clinical Trials Analysis
18.1 Analysis by Trial Registration Year
18.2 Analysis by Trial Status
18.3 Analysis by Trial Phase
18.4 Analysis by Therapeutic Area
18.5 Analysis by Geography
19 Funding and Investment Analysis
19.1 Analysis by Funding Instances
19.2 Analysis by Type of Funding
19.3 Analysis by Funding Amount
19.4 Analysis by Leading Players
19.5 Analysis by Leading Investors
19.6 Analysis by Geography
20 Partnership and Collaborations Analysis
20.1 Analysis by Partnership Instances
20.2 Analysis by Type of Partnership
20.3 Analysis by Leading Players
20.4 Analysis by Geography
21 Supplier Landscape
21.1 F. Hoffmann-La Roche Ltd
21.1.1 Financial Analysis
21.1.2 Product Portfolio
21.1.3 Demographic Reach and Achievements
21.1.4 Company News
21.1.5 Certifications
21.2 Bausch & Lomb
21.2.1 Financial Analysis
21.2.2 Product Portfolio
21.2.3 Demographic Reach and Achievements
21.2.4 Company News
21.2.5 Certifications
21.3 Novartis AG
21.3.1 Financial Analysis
21.3.2 Product Portfolio
21.3.3 Demographic Reach and Achievements
21.3.4 Company News
21.3.5 Certifications
21.4 Pfizer, Inc.
21.4.1 Financial Analysis
21.4.2 Product Portfolio
21.4.3 Demographic Reach and Achievements
21.4.4 Company News
21.4.5 Certifications
21.5 AbbVie Inc.
21.5.1 Financial Analysis
21.5.2 Product Portfolio
21.5.3 Demographic Reach and Achievements
21.5.4 Company News
21.5.5 Certifications
21.6 Santen Pharmaceutical Co., Ltd.
21.6.1 Financial Analysis
21.6.2 Product Portfolio
21.6.3 Demographic Reach and Achievements
21.6.4 Company News
21.6.5 Certifications
21.7 Ophthotech Corporation
21.7.1 Financial Analysis
21.7.2 Product Portfolio
21.7.3 Demographic Reach and Achievements
21.7.4 Company News
21.7.5 Certifications
21.8 Alimera Sciences
21.8.1 Financial Analysis
21.8.2 Product Portfolio
21.8.3 Demographic Reach and Achievements
21.8.4 Company News
21.8.5 Certifications
21.9 GSK plc.
21.9.1 Financial Analysis
21.9.2 Product Portfolio
21.9.3 Demographic Reach and Achievements
21.9.4 Company News
21.9.5 Certifications
21.10 Bayer AG
21.10.1 Financial Analysis
21.10.2 Product Portfolio
21.10.3 Demographic Reach and Achievements
21.10.4 Company News
21.10.5 Certifications
22 Neovascular Age-Related Macular Degeneration Treatment - Distribution Model (Additional Insight)
22.1 Overview
22.2 Potential Distributors
22.3 Key Parameters for Distribution Partner Assessment
23 Key Opinion Leaders (KOL) Insights (Additional Insight)
24 Company Competitiveness Analysis (Additional Insight)
24.1 Very Small Companies
24.2 Small Companies
24.3 Mid-Sized Companies
24.4 Large Companies
24.5 Very Large Companies
25 Payment Methods (Additional Insight)
25.1 Government Funded
25.2 Private Insurance
25.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The market attained a value of about USD 11 billion in 2022, driven by the rising prevalence of neovascular AMD.
The market is anticipated to grow at a CAGR of 7.51% during the forecast period of 2024-2032 and reach a market value of USD 21.1 billion by 2032.
Increasing collaborative efforts between pharmaceutical companies, research institutions, and healthcare providers are contributing to more research and development activities to acquire better treatment solutions for AMD is among the major factors driving the market growth.
The rising emphasis and trials on targeted therapies and genetic testing to identify subgroups of patients who may respond better to specific treatments is among the major trends influencing the market growth.
The 7 major markets for neovascular age-related macular degeneration treatment include United States, EU-4 and the United Kingdom, and Japan. EU-4 includes Germany, France, Italy, and Spain.
The key drugs available in the market are Ranibizumab, Aflibercept, Bevacizumab, Brolucizumab, and Faricimab, among others.
There are two types of diseases dry AMD and wet AMD.
The age groups include people who are less than 60, between 60 to 80, and more than 80.
The disease stages include early-stage AMD, intermediate stage AMD, and late-stage AMD.
On basis of gender, market is segmented into male and female.
The distribution channels include hospital pharmacy, retail pharmacy, and online pharmacy.
Key players involved in the market are F. Hoffmann-La Roche Ltd, Bausch & Lomb, Novartis AG, Pfizer, Inc., AbbVie Inc., Santen Pharmaceutical Co., Ltd., Ophthotech Corporation, Alimera Sciences, GSK plc., and Bayer AG.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 3299
$2999
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 6599
$5999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 8799
$7999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 9899
$8999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER